Katsuyama K, Shichiri M, Marumo F, Hirata Y
Endocrine-Hypertension Division, Second Department of Internal Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Arterioscler Thromb Vasc Biol. 1998 Nov;18(11):1796-802. doi: 10.1161/01.atv.18.11.1796.
Nitric oxide (NO) is known to have antiatherogenic and anti-inflammatory properties, but its effects on the cytokine-induced nuclear factor-kappa B (NF-kappaB) activation pathway in relation to the regulation of inducible nitric oxide synthase (iNOS) gene in vascular smooth muscle cells (VSMCs) remain elusive. To elucidate the roles of NO in the regulation of cytokine-induced NF-kappaB activation and consequent iNOS gene expression, we studied the effects of NO donors [(+/-)-(E)-ethyl-2-[(E)-hydroxyamino]-5-nitro-3-hexeneamide (NOR3) and sodium nitroprusside] on interleukin (IL)-1beta-induced NF-kappaB activation and IkappaB-alpha degradation and subsequent iNOS expression in rat VSMCs. Northern blot and Western blot analyses demonstrated that NO donors decreased IL-1beta-induced iNOS mRNA and protein expression. Electrophoretic mobility shift assay using synthetic oligonucleotide corresponding to the downstream NF-kappaB site of rat iNOS promoter as a probe showed that NOR3 inhibited IL-1beta-induced NF-kappaB activation and its nuclear translocation, as demonstrated with immunocytochemical study. These effects were independent of guanylate cyclase activation; an inhibitor of soluble guanylate cyclase (1H-oxadiazolo-1,2,4-[4,3-alpha]quinoxaline-1-one) had no effect on NOR3-induced inhibition of NF-kappaB activation or iNOS mRNA expression by IL-1beta, and a cGMP derivative (8-bromo-cGMP) failed to mimic the effects of NO donors. Western blot analysis using anti-IkappaB-alpha and anti-phospho-IkappaB-alpha antibodies revealed that IL-1beta induced a transient degradation of IkappaB-alpha preceded by a rapid appearance of phosphorylated IkappaB-alpha, both of which were completely blocked by NOR3. A proteasome inhibitor (MG115) blocked IL-1beta-induced transient degradation of IkappaB-alpha and stabilized the appearance of phosphorylated IkappaB-alpha stimulated by IL-1beta. NOR3 inhibited the appearance of IL-1beta-induced phosphorylated IkappaB-alpha even in the presence of MG115. Our results indicate that an inhibitory action by NO on cytokine-induced NF-kappaB activation and iNOS gene expression is due to its direct blockade on phosphorylation and subsequent degradation of IkappaB-alpha via the cGMP-independent pathway in rat VSMCs.
已知一氧化氮(NO)具有抗动脉粥样硬化和抗炎特性,但其在血管平滑肌细胞(VSMC)中对细胞因子诱导的核因子-κB(NF-κB)激活途径以及诱导型一氧化氮合酶(iNOS)基因调控方面的作用仍不清楚。为了阐明NO在细胞因子诱导的NF-κB激活调控以及随后的iNOS基因表达中的作用,我们研究了NO供体[(±)-(E)-乙基-2- [(E)-羟基氨基]-5-硝基-3-己烯酰胺(NOR3)和硝普钠]对白细胞介素(IL)-1β诱导的大鼠VSMC中NF-κB激活、IκB-α降解以及随后的iNOS表达的影响。Northern印迹和Western印迹分析表明,NO供体降低了IL-1β诱导的iNOS mRNA和蛋白表达。使用与大鼠iNOS启动子下游NF-κB位点对应的合成寡核苷酸作为探针进行的电泳迁移率变动分析表明,NOR3抑制了IL-1β诱导的NF-κB激活及其核转位,免疫细胞化学研究也证实了这一点。这些作用与鸟苷酸环化酶激活无关;可溶性鸟苷酸环化酶抑制剂(1H-恶二唑并-1,2,4-[4,3-α]喹喔啉-1-酮)对NOR3诱导的IL-1β抑制NF-κB激活或iNOS mRNA表达没有影响,并且环鸟苷酸衍生物(8-溴-环鸟苷酸)未能模拟NO供体的作用。使用抗IκB-α和抗磷酸化IκB-α抗体进行的Western印迹分析显示,IL-1β诱导IκB-α短暂降解,之前有磷酸化IκB-α快速出现,这两者均被NOR3完全阻断。蛋白酶体抑制剂(MG115)阻断了IL-1β诱导的IκB-α短暂降解,并稳定了IL-1β刺激的磷酸化IκB-α的出现。即使在存在MG115的情况下,NOR3也抑制了IL-1β诱导的磷酸化IκB-α的出现。我们的结果表明,NO对细胞因子诱导的NF-κB激活和iNOS基因表达的抑制作用是由于其通过大鼠VSMC中不依赖环鸟苷酸的途径直接阻断IκB-α的磷酸化及其随后的降解。